Sofosbuvir treatment and hepatitis C virus infection

作     者：Masato Nakamura Tatsuo Kanda Yuki Haga Reina Sasaki Shuang Wu Shingo Nakamoto Shin Yasui Makoto Arai Fumio Imazeki Osamu Yokosuka 

作者机构：Department of Gastroenterology and NephrologyChiba UniversityGraduate School of MedicineChiba 260-8670Japan Department of Molecular VirologyChiba UniversityGraduate School of MedicineChiba 260-8677Japan Safety and Health OrganizationChiba UniversityChiba 263-8522Japan 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2016年第8卷第3期

页      面：183-190页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Japan Society for the Promotion of Science  JSPS  (13F03100) 

主　　题：Hepatitis C virus Interferon Interferonfree Genotype Sofosbuvir 

摘      要：Hepatitis C virus(HCV) infection is a serious problem *** use of interferon-based therapy has made HCV eradication *** recent appearance of direct-acting antiviral agents(DAAs) has changed HCV *** the use of DAAs with peginterferon and ribavirin has improved treatment ***,the combination of different orally administered DAAs has enabled interferon-free therapy with much higher efficacy and *** particular,sofosbuvir,a nucleotide-based NS5 B inhibitor,prevents HCV RNA synthesis by acting as a chain terminator.Treatment with sofosbuvir has attained an extremely high rate of sustained virologic *** current review summarizes the efficacy and safety of sofosbuvir therapy.